Early onset HER2-positive breast cancer is associated with germlineTP53mutations

Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human

(2010) V Shahabi et al.   CANCER GENE THERAPY

Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies

(2010) I Goldstein et al.   CANCER GENE THERAPY

p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines

(2010) Lynnette Fernandez-Cuesta et al.   INTERNATIONAL JOURNAL OF CANCER

TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes

(2010) M. W. G. Ruijs et al.   JOURNAL OF MEDICAL GENETICS

A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations

(2010) J. R. F. Wilson et al.   JOURNAL OF MEDICAL GENETICS

Radio-induced malignancies after breast cancer post-operative radiotherapy in patients with Li- Fraumeni syndrome

(2010) Steve Heymann et al.   Radiation Oncology

Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families Withp53Germline Mutations

(2009) Kelly D. Gonzalez et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast Magnetic Resonance Imaging: An Overview for Nonradiologists

(2009) Laurie Margolies et al.   MOUNT SINAI JOURNAL OF MEDICINE

Recent advances in p53 research: an interdisciplinary perspective

(2008) M Olivier et al.   CANCER GENE THERAPY

F18-Fluorodeoxyglucose–Positron Emission Tomography/Computed Tomography Screening in Li-Fraumeni Syndrome

(2008) Serena Masciari   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION